Global Cas Nuclease Market Top Major Players 2024, Forecast To 2033
12 Nov, 2024
The Cas nuclease market has grown rapidly, expected to expand from $2.75 billion in 2023 to $3.27 billion in 2024 at a CAGR of 18.9%. Growth drivers include a rise in genome editing, increased funding for biotechnology research, demand for personalized medicine, government support for genetic research, and a growing incidence of genetic disorders. The Cas nuclease market is expected to grow to $6.56 billion by 2028, with a CAGR of 19.0%. This growth is driven by increasing investment in gene editing, demand for therapeutic genome editing, regulatory approvals for gene therapies, and the rise of epigenome editing. Trends include CRISPR adoption for rare disease treatment, agricultural gene editing, synthetic RNA-guided nucleases, and the growth of ethical discussions surrounding genome editing.
Major Driver In The Cas Nuclease Market
Increased investment in biotechnology is anticipated to drive the Cas nuclease market, spurred by advancements in gene-editing technologies and a growing demand for innovative medical treatments. In the first half of 2024, the UK's life sciences sector raised $2.61 billion, surpassing the $2.38 billion raised in all of 2023. This surge in funding highlights the expanding applications of biotechnology, further stimulating the growth of the Cas nuclease market. As gene-editing applications continue to gain momentum, the Cas nuclease market is expected to grow significantly, reaching $X billion in 2024 and $Y billion by 2028.
Request A Free Sample Of The Cas Nuclease Market ReportCas Nuclease Market Competitive Landscape
Thermo Fisher Scientific Inc., AstraZeneca PLC, Merck KGaA, Vertex Pharmaceuticals, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Promega Corporation, GenScript Biotech Corporation, CRISPR Therapeutics AG, Integrated DNA Technologies Inc., Takara Bio Inc., New England Biolabs Inc., Horizon Discovery Group plc, OriGene Technologies Inc., Applied Biological Materials Inc. (ABM), Synthego Corporation, Novoprotein Scientific Inc., genOway, Precision BioSciences, Editas Medicine, Creative Biolabs, Cellectis, Caribou Biosciences, Addgene
Key Cas Nuclease Market Trend
Companies in the Cas nuclease market are investing in CRISPR-based gene editing technology to stay ahead. In November 2023, Vertex Pharmaceuticals and CRISPR Therapeutics received approval for CASGEVY, a CRISPR-based gene therapy for treating sickle cell disease and transfusion-dependent beta thalassemia in patients aged 12 and older. This approval marks the first CRISPR/Cas9 therapy to treat genetic disorders.
Purchase The Global Cas Nuclease Market Report Directly And Get A Swift DeliveryGlobal Cas Nuclease Market Segmentation
The cas nuclease market covered in this report is segmented –
1) By Type: Cas9, Cas12, Cas13, Other Cas Nucleases
2) By Delivery Method: Viral Vectors, Lipid Nanoparticles, Electroporation, Microinjection, Transposons
3) By Distribution Channel: Direct Sales, Distributor
4) By Application: Gene Editing Cell Line Construction, Animal Models, Bioagriculture, Gene Therapy, Other Applications
5) By End-User: Academic And Government Research Institutions, Biotechnology And Pharmaceutical Companies, Contract Research Organizations (CROS), Agricultural Biotechnology Companies, Other End-Users
By Geography:The regions covered in the cas nuclease market report areAustralia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the Cas nuclease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The Cas Nuclease Global Market Report 2024 furnishes information about the global cas nuclease market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.